FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileRetension Pharmaceuticals Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
RTSN
Retension Pharmaceuticals Inc. Stock AnalysisComprehensive stock analysis for Retension Pharmaceuticals Inc. (RTSN) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisRTSN
RTSN
Retension Pharmaceuticals Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
RTSN
  1. Home
  2. Stocks
  3. Retension Pharmaceuticals Inc.
RP

Retension Pharmaceuticals Inc.

🇺🇸RTSN•NASDAQ
RP

Retension Pharmaceuticals Inc.

🇺🇸RTSN•NASDAQ
Market cap
$52.09M
Sentiment

Your view on RTSN

Mkt Cap
$52.09M
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Retension Pharmaceuticals Inc.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
CEO
Eric L. Keller
Headquarters
1104 West Broad Street 1029, Falls Church, VA, US
Industry
Medical - Pharmaceuticals
Sector
Healthcare
CEO
Eric L. Keller
Headquarters
1104 West Broad Street 1029, Falls Church, VA, US
Description

Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases.

Its product, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension.

The company was founded by Eric Keller and Paul Sweetnam in 2023 and is headquartered in Falls Church, VA.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Retension Pharmaceuticals Inc. from FRC's valuation model, read against the market price. RTSN last traded at $13.89; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Retension Pharmaceuticals Inc.. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Retension Pharmaceuticals Inc.. Retension Pharmaceuticals Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Retension Pharmaceuticals Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Retension Pharmaceuticals Inc.. Retension Pharmaceuticals Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold RTSN12 companies · 8 funds

More Medical - Pharmaceuticals companies

Market cap

  • GHTIG-H-3 International Inc.OTC
  • GRPIGrupo International Inc.OTC$1,043
  • GSACGelStat CorporationOTC$247,192
  • GWLLGoldenwell Biotech, Inc.OTC$104M
  • HADVHealth Advance Inc.OTC$48,284
  • HELPCybin Inc. Common StockNASDAQ$427M
  • HEWAHealthWarehouse.com, Inc.OTC$5M
  • HITIHigh Tide Inc.NASDAQ$211M
  • HITI.VHigh Tide Inc.TSXV$325M
  • HTPRFHTC Purenergy Inc.OTC$8,153
  • HTSUYHisamitsu Pharmaceutical Co., Inc.OTC$1.9B
  • HYHYHydrogen Hybrid Technologies, Inc.OTC$9,375

ETFs holding Retension Pharmaceuticals Inc.

% of the fund

  • VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
  • VXFVanguard Extended Market ETF$30.2B in assets0.00%
  • VTWOVanguard Russell 2000 ETF$16.6B in assets0.00%
  • VTWGVanguard Russell 2000 Growth ETF$1.4B in assets0.00%
  • VUN.TOVanguard U.S. Total Market Index ETF$20.1B in assets0.00%
  • VTWVVanguard Russell 2000 Value ETF$1.3B in assets0.00%
  • VEQT.TOVanguard All-Equity ETF Portfolio$17.6B in assets0.00%
  • VGRO.TOVanguard Growth ETF Portfolio$10.9B in assets0.00%

Largest holders first, then the funds most concentrated in RTSN.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Retension Pharmaceuticals Inc., and how their positions are changing. At a $52.1M market value, institutional positions materially move Retension Pharmaceuticals Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Retension Pharmaceuticals Inc. executives and directors. Shares of Retension Pharmaceuticals Inc. have traded between $9.66 and $18.64 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

About this section

U.S. Senate disclosures naming Retension Pharmaceuticals Inc.. Retension Pharmaceuticals Inc. is a $52.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming Retension Pharmaceuticals Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Retension Pharmaceuticals Inc.. Coverage tracks Retension Pharmaceuticals Inc. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Retension Pharmaceuticals Inc.

RTSN Analysis
Weak
Past4
Growth1
Health1
Profit1
Value1

News

Latest Market News